Percutaneous Atherectomy Systems Market: By Mechanism of Action (Orbital, Photoablative, Rotational/Aspirational, and Excisional/Directional), By End-User (Hospitals and Surgical Centres, Ambulatory Care Centres, and Others) and Geography 2019-2030

The percutaneous atherectomy systems market was valued at USD 832.5 million in 2023 and is projected to grow at 11.4% CAGR over the forecast years to reach USD 1772.5 million by 2030. The percutaneous atherectomy systems market is experiencing significant growth, driven by several factors such as the rising prevalence of diseases, increasing geriatric population, growing preference for minimally invasive surgical procedures, and higher success rate. The ease of application of percutaneous atherectomy devices increases with factors such as the rising incidence of cardiovascular diseases, the steadily growing geriatric population, and the trend towards minimally invasive treatments. Atherosclerosis & other cardiovascular conditions are the leading causes of morbidity & mortality worldwide. UK 2.6 million people identify that heart artery narrowing possibly leads to heart attack or angina.

According to the estimates of the American Heart Association, 16 million Americans are suffering from coronary artery diseases, which have emerged as the number one killer in the US. The ageing population is more prone to these diseases due to arterial fitness changes with age. The increasing geriatric population meets the growing demand for percutaneous atherectomy devices. Despite the growth, some constraints will hinder market growth such as high costs and high restenosis rate. Technology advancement, increasing awareness, collaboration and partnership, and market expansion are the trends and opportunities in the percutaneous atherectomy systems market.

Percutaneous Atherectomy Systems Market Key Developments:

• In February 2023, Abbott announced that it would acquire Cardiovascular Systems, Inc. Under the agreement, Abbott will acquire Cardiovascular Systems, Inc. for approximately USD 890 million, or USD 20 per share. This acquisition will enable the medical devices portfolio of Cardiovascular Systems, Inc. to be integrated into Abbott's product portfolio, which is already dedicated to the treatment of vascular diseases.
• In December 2021, Koninklijke Philips N.V. announced its acquisition of Vesper Medical Inc., a medical technology company based in the USA and engaged majorly in developing minimally invasive peripheral vascular devices. Through this acquisition, the diagnostic and therapeutic devices portfolio available with Koninklijke Philips N.V. were further strengthen by adding the innovative venous stent portfolio of Vesper Medical Inc.